Intracisternal delivery of PEG-coated gold nanoparticles results in high brain penetrance and long-lasting stability
The increasing use of gold nanoparticles (AuNPs) in the field of neuroscience instilled hope for their rapid translation to the clinical practice. AuNPs can be engineered to carry therapeutics or diagnostics in the diseased brain, possibly providing greater cell specificity and low toxicity. Although there is a general enthusiasm for these tools, we are in early stages of their development. Overall, their brain penetrance, stability and cell specificity are critical issues that must be addressed to drive AuNPs to the clinic.
We studied the kinetic, distribution and stability of PEG-coated AuNPs in mice receiving a single injection into the cisterna magna of the 4th ventricle. AuNPs were conjugated with the fluorescent tag Cy5.5 (Cy5.5-AuNPs) to track their in vivo distribution. Fluorescence levels from such particles were detected in mice for weeks. In situ analysis of brains by immunofluorescence and electron microscopy revealed that Cy5.5-AuNPs penetrated the brain parenchyma, spreading in the CNS parenchyma beneath the 4th ventricle. Cy5.5-AuNPs were preferentially found in neurons, although a subset of resting microglia also entrapped these particles.
Our results suggest that the ICM route for delivering gold particles allows the targeting of neurons. This approach might be pursued to carry therapeutics or diagnostics inside a diseased brain with a surgical procedure that is largely used in gene therapy approaches. Furthermore, this approach could be used for radiotherapy, enhancing the agent’s efficacy to kill brain cancer cells.
KeywordsGold nanoparticles Intra cisterna magna In vivo analysis
central nervous system
blood brain barrier
intra cisterna magna
transmission electron microscopy
Inductively Coupled Plasma-Optical Emission Spectrometers
dynamic light scattering
region of interest
A wide interest in the field of nanomedicine involves structurally different nanovectors, and in particular functionalized nanoparticles. Given their excellent biocompatibility and stability, nanoparticles are used to deliver drugs, genes, fluorescent labels, imaging agents, and enhancing radiotherapy tools. More recently, they were proposed as antiviral agents [1, 2]. Accordingly, more than 200 nano-objects targeted toward nanomedicine are currently approved for clinical trials in patients, while a larger number is engaged in pre-clinical studies .
Despite encouraging results indicate that nanovectors are reliable tools to treat a considerable number of pathologies, their use in disorders of central nervous system (CNS) is hampered by some limitations. A major challenge for their usage in CNS is their limited ability to cross the blood brain barrier (BBB), which often prevents to attain effective pharmacokinetic levels of therapeutics in the brain. Recent advances led to the generation of improved nanoparticles showing increased CNS penetration , therefore opening new avenues in basic and clinical neuroscience . Among such particles, metallic nanoparticles are extremely attractive tools for their biophysical characteristics . Gold nanoparticles (AuNPs) display unique optical and electronic properties to be considered reliable tools for drug/gene delivery, biomedical imaging , photothermal and microwave therapies . AuNPs can be easily and uniformly functionalized with different chemical groups, allowing these particles to target specific locations in different organs as well as to reduce toxicity [9, 10]. AuNPs display size-dependent kinetics and distribution when injected in tissues [11, 12]. The intravenous injection of AuNPs results in accumulation of particles in several organs, including the brain. Interestingly, particles with sizes in the range of 15–50 nm cross the BBB better than particles with bigger diameters [12, 13]. The surface functionalization has a great impact on pharmacokinetic properties of AuNPs . For example, transferrin-coated nanoparticles enter the brain through transcytosis and are more BBB-penetrant than other types of functionalized AuNPs . Polyethylene glycol (PEG) coating of AuNPs increases their solubility and reduces toxicity . Indeed, in a model of spinal cord contusion the local injection of PEG-coated AuNPs improved functional recovery and attenuated demyelination . Insulin coated AuNPs crossed the BBB, reaching the brain with concentrations that are around 5% of the total injected dose . However, 2 days after the delivery, the concentration of particles in the brain drops to values around 1–2% of the injected dose . Imaging studies further corroborate these observations, showing that once AuNPs get into the brain, they rapidly disappear [17, 18, 19, 20, 21]. Intra-carotid injection of AuNPs increases the penetrance of particles in the brain, although their diffusion in the parenchyma is limited to few microns from the visible vessels . Repeated treatments can increase the penetrating amount of AuNPs in the brain [6, 17, 23], although an uncontrolled accumulation of AuNPs in neurons could create some adverse effects, such as alterations of the firing properties of neurons . Therefore, we must take in consideration such aspect if we plan therapeutic strategies for chronic diseases/applications.
The use of intra-parenchymal injections or the implantation of catheters, both by-passing the BBB, have the great limit of requiring invasive surgical procedures. Likely, both approaches can trigger undesired local inflammatory responses [25, 26]. A strategy to increase the penetrance and the permanence of appropriate concentrations of AuNPs in the CNS, that avoids the use of serial injections, requires alternative routes of administrations. In a model of focal lesion, such as the spinal cord injury, PEG-AuNPs injected in two sites that flanked the lesion epicenter efficiently supported the functional recovery of mice . In spite of this noteworthy result, we can speculate that such procedure will find some limitations in diseases featuring large or disseminated brain lesions, such as multiple sclerosis (MS). Among alternative approaches to delivery AuNPs, the intrathecal route offers several advantages and it has been used to delivery drugs, as well as to infuse the brain with anesthetics, trophic factors and antibodies, although it has never been used to deliver nanoparticles [27, 28]. Experiments of gene delivery in mice clearly demonstrated that the intra cisterna magna (ICM) route is safe [29, 30, 31]. Indeed, gene therapy experiments showed that ICM injection of lentivirus leads viruses to diffuse consistently in all cerebrospinal fluid (CSF) spaces, infecting both choroidal and ependymal cells .
Growing evidence from several studies suggests that non-invasive imaging procedures to track the bio-distribution of AuNPs at different time points are excellent tools to accomplish the goal of using AuNPs in a clinical setting. The in vivo near infrared optical imaging of fluorescent-coated AuNPs is a relatively novel fluorescence imaging (FLI) approach that overcomes some previous limits of in vivo imaging, offering an excellent resolution and, above all, a limited invasiveness .
In this study, we characterized mice receiving ICM delivery of PEG functionalized and Cy5.5 labelled AuNPs (Cy5.5-AuNPs). We observed robust accumulation of Cy5.5-AuNPs in the CNS of mice, receiving a single injection of particles. Injected mice did not show signs of distress or pain. Remarkably, in vivo imaging showed detectable signals for more than 20 days. Confocal and electron microscopy analyses revealed that Cy5.5-AuNPs internalization in scattered neurons along the CNS parenchyma with some of them located several hundred microns far from the ependymal layer.
Synthesis and characterization of Cy5.5-AuNPs
In vitro characterization of Cy5.5-AuNPs toxicity
In vivo delivery of Cy5.5-AuNPs
We next administered AuNPs to adult mice, establishing their pharmacokinetic distribution in the brain. We initially performed a single s injection of Cy5.5-AuNPs in the tail vein of mice. We used an equal amount of soluble Cy5.5 to establish control mice. We recorded FLI 5 days after the delivery of Cy5.5-AuNPs. We calculated the fluorescence ratio (FR) in each animal (see “Methods” sections for details). However, fluorescence levels measured in both groups did not exceed the background levels, and did not allow a robust calculation of FR levels (Additional file 2: Figure S2A). We next examined Cy5.5 fluorescence in the cortical wall of these mice using the NeuN marker to identify neurons. However, levels of Cy5.5 measured in both groups were did not exceed the general background (Additional file 2: Figure S2B and C).
We subsequently performed an intra parenchymal injection of Cy5.5-AuNPs targeting the presumptive somatosensory cortex of mice. Due to the small volume of Cy5.5-AuNPs that we delivered in brains, the fluorescence levels of Cy5.5 were hardly detectable in living mice. However, we detected signals that were more robust when we scored FLI in isolated brains collected 5 days after the injection of particles (Additional file 3: Figure S3A). Signals were concentrated in spots localized in the presumptive somatosensory cortex (Additional file 3: Figure S3A). FLI of 500 µm thick coronal slabs further confirmed that highest Cy5.5 signal was deriving from the somatosensory cortex (Additional file 3: Figure S3B). AuNPs with a size of 20 nm absorb 530 nm wavelength and emit a wavelength that peaks at 610 nm, which is sufficiently intense to be detected by a fluorescence microscope . Therefore, we performed serial imaging of adjacent sections, scoring the somatosensory cortical wall. We labelled 20 µm thick sections for NeuN and by confocal microscopy we observed the almost perfect co-localization of Cy5.5 signals with Au signals (Additional file 4: Figure S4A, B) in several cortical NeuN+ cells (Additional file 4: Figure S4C, D).
We next labelled parallel sections for the microglia/macrophages Iba1 to establish whether the injection procedures may alter the cortical morphology. We used Iba1 to label reactive microglia/macrophages, both associated to focal CNS injuries . Iba1+ cells were scored in regions surrounding the site of the injection (ipsilateral cortex) as well as in the controlateral cortex, not receiving any manipulation (Additional file 3: Figure S3C, D). We observed a moderate to high gliosis featured by a significant increase of Iba1+ cells in the ipsilateral cortex (Additional file 3: Figure S3E). Therefore, we reasoned that the relative high abundance of Iba1+ Cy5.5-AuNPs+ cells in the ipsilateral cortex could mirror the activation of phagocytosis (Additional file 3: Figure S3F), a classical phenomenon that occurs in response to tissue damage .
Ex-vivo localization of Cy5.5-AuNPs in ICM injected brains
A considerable number of putative drugs lacks the ability to penetrate the BBB, and for this limitation none of them were further pursued as therapeutics. The functionalization of nanovectors with these molecules could, in principle, overcome such limitation, allowing their diffusion in diseased brains. Thus, the physiological barrier represented by the BBB could be crossed by nanoparticle-supported drugs able then to interact with their targets. However, after an initial enthusiasm for this approach, it became clear that the general efficiency of nanovectors to cross the BBB was modest [17, 18, 19, 20, 21]. In this context, AuNPs have attracted attention for their safety and biophysical characteristics . The direct injection of AuNPs in the CNS parenchyma is attractive, although our data indicate that such procedure may generate tissue damage and microglia activation. Intranasal administration of AuNPs, conversely, leads to their uptake in different brain regions and is a promising method for the BBB passage of nanoparticles, although the regional distribution in the brain of molecules may vary from substance to substance, and additional studies are needed to validate this approach . Repeated intravenous injections of nanoparticles, often using high dosages to achieve BBB permeation, could induce their accumulation in the liver causing inflammation and apoptosis and may alter neuronal functions [41, 44]. A recent study, showing in vivo instability of coated AuNPs, adds a further layer of complexity, suggesting that using AuNPs to deliver molecules as well as their tracking in living animals may be influenced by a certain degree of molecular instability and/or cell metabolism . Indeed, fluorochrome-coated AuNPs are processed by lysosomes in the liver, and molecules tagging AuNPs can be cleaved by proteolysis . These experimental observations should be considered in the interpretation of distribution studies after systemic administration of AuNPs.
For these reasons, we attempted to deliver Cy5.5-AuNPs directly in the brain using a single intrathecal injection. This approach has been extensively used in the past to deliver lentiviral particles and drugs . ICM injections are well characterized for such vectors, but little is known regarding their use to deliver AuNPs. Our experimental evidence shows that this route of administration does not induce signs of distress in mice. It was surprising to observe, using in vivo optical imaging, that mice receiving Cy5.5-AuNPs showed retention of particles in the brain for more than 20 days. Furthermore, in this experimental setting we observed that the fluorescence emitted by both Cy5.5 and Au in brain sections were perfectly overlapped, suggesting a high stability of the Cy5.5 tag grafted on Au surfaces. These results suggest that functionalized AuNPs entering the CNS escape the degradation and are more stable in the CNS than in other organs, such as the liver . The diffusion of Cy5.5-AuNPs in the CNS parenchyma was surprisingly wide, and some neurons positive for them localized several hundreds of microns away from the ventricular cavity. The mechanism of diffusion of such particles is still unknown, but we could speculate that these such small particles can passively diffuse in the extracellular matrix before being up taken by endocytosis. However, double staining of Cy5.5-AuNPs and markers of neurons, microglia and astrocytes, revealed that AuNPs uptake was prominent in neurons, while only few microglia efficiently incorporate such particles. The high stability of Cy5.5-AuNPs in the brain can be due to their rapid uptake by cells, that prevents their removal by convective lymphatic fluxes of the CSF . In addition, PEG functionalization is helping to prevent their uptake by peri-vascular macrophage, thus increasing the half-life of Cy5.5-AuNPs. Thus, our study clarifies the routes and the mechanisms of functionalized AuNPs distribution, kinetic and stability after entering the brain. We observed a relevant AuNPs uptake in neurons and microglia far from the CM. We also observed their uptake in intracellular compartments (mainly lysosomes), suggesting a movement of Cy5.5-AuNPs through membrane compartments.
We have demonstrated that Cy5.5-AuNPs are highly stable upon their entry into the CNS, probably due to their resistance to cellular metabolism. We have shown that AuNPs are efficiently taken up by neurons and concentrate into intracellular compartments. In principle, their long stability and their ability to target intracellular vesicles in neurons could be exploited in disorders showing disrupted lysosomal homeostasis in neurons, such as the wide family of Lysosomal Storage Diseases . AuNPs could be also exploited in brain cancer radiotherapy, because PEG-coated AuNPs can accumulate in brain tumors and can be efficiently used for increasing radiotherapy efficiency . Thus, our experimental evidence showing a long-lasting PEG-AuNPs accumulation in neurons upon intrathecal injection suggests that this route of administration could be potentially used for radiotherapy enhancing agents in CNS tumors as well as in Lysosomal Storage Diseases.
Synthesis of PEG-functionalized AuNPs
Synthesis of PEG-functionalized AuNPs was performed following our published methods . Cyanine 5.5 (Cy5.5) NHS ester was purchased from Lumiprobe (Hunt Valley, Maryland 21030, USA) and stored in the dark at − 20 °C. All glassware used for AuNP synthesis was cleaned with aqua regia (HCl(37%)/HNO3(65%) 3/1). A water mixture of sodium citrate (9 ml, 2%), HAuCl4·3H2O (7.0 ml, 10 mM) and AgNO3 (420 μl, 0.1%) was stirred at room temperature for 6 min and added to 250 ml of boiling water. The mixture was stirred (750 rpm) for 1 h at 100 °C, then the seed solution was allowed to cool to room temperature. Glycerol (5 ml) was added and the suspension was stirred for 15 min. A second aliquot of sodium citrate (10 ml, 1%), HAuCl4 (7.5 ml, 10 mM) and AgNO3 (426 μl, 0.1%) was separately stirred for 6 min and then added to the colloidal solution, followed immediately by a solution of hydroquinone (8 ml, 1%). The resulting solution was allowed to age, stirring at 750 rpm for 1 h at room temperature. The reddish solution of citrate-capped AuNPs was directly used without purification to functionalize the gold surface. A mixture of CH3O-PEG5000-SH/NH2-PEG5000-SH 9/1 (30 mg, Rapp Polymer GmbH) was dissolved in 5 ml of water and NaOH (8 mg) and added to the mixture containing AuNPs while argon was bubbled in the solution (for 5 min). The reaction mixture was stirred for 48 h at room temperature. PEG-AuNPs were then concentrated and purified by mean of Amicon centrifugal Filter units to a final volume of 11 ml.
Synthesis of Cy5.5-AuNPs
Five ml of PEG-functionalized AuNPs (10% PEG-NH2), in milliQ water, were filtered by centrifugal filtration (10,000 MWCO, Vivaspin filters) to remove the solvent, and were re-suspended in borate buffer at pH 8. To this solution, Cy5.5-NHS ester (450 µg, 0.00063 mmol, Lumiprobe-Hunt Valley, Maryland 21030, USA) dissolved in DMSO (500 µl) was added at room temperature. We adjusted pH to 8.5 by adding NaOH 0.2 N, and the reaction mixture was stirred at room temperature in the dark for ca. 18 h. Then, the solvent was removed by centrifugal filtration (10,000 MWCO, Vivaspin filters) and Cy5.5-AuNPs were washed with tBuOH/H2O 1:1 until the collected washing solution was colorless (the absence of Cy5.5 adsorption was checked through UV–Vis spectroscopy). Finally, Cy5.5-AuNPs were washed with milliQ water to remove tBuOH traces, were dissolved in 5 ml milliQ water and stored at 4 °C.
Characterization of Cy5.5-AuNPs
Dynamic light scattering (DLS) was employed to measure hydrodynamic diameter and Zeta-potential, determined by using a 90 Plus Particle Size Analyzer from Brookhaven Instrument Corporation (Holtsville, NY) operating at 15 mW of a solid-state laser (λ = 661 nm), using a scattering angle of 90°, equipped with an AQ-809 electrode, operating at applied voltage of 120 V. DLS samples were prepared by filtration with a 0.45 μm cellulose acetate syringe filter before loading into the cuvette, in order to remove large interfering particulate matter. Each sample was allowed to equilibrate for 3 min prior to start the measurement. Three to ten independent measurements of 60 s duration were performed, at 25 °C. The hydrodynamic diameter calculation was performed using Mie theory. The absolute viscosity and refractive index values of the medium were respectively set to 0.911 cP and 1.334. The Zeta-potential was automatically calculated from electrophoretic mobility based on the Smoluchowski theory. A viscosity of 0.891 cP, a dielectric constant of 78.6, and a Henry function of 1.5 were used for the calculations. UV/Vis spectra were recorded on an Agilent 8453 instrument by using a disposable cuvette with 1 cm optical path length for the measurements. Transmission electron microscopy micrographs have been collected using a TEM-Zeiss LIBRA 200FE instrument, equipped with: 200 kV FEG, in column second-generation omega filter for energy selective spectroscopy (EELS) and imaging (ESI), HAADF STEM facility, EDS probe for chemical analysis, integrated tomographic HW and SW systems. TEM specimens were prepared by dropping an aqueous solution of AuNPs onto a carbon-coated copper grid (300 mesh) and evaporating the solvent. The particle size distribution was estimated by using ITEM-TEM Imaging platform—Olympus Soft Imaging Solutions. The number of measured nanoparticles for each sample resulted to be around 250. Au concentration was determined via Inductively Coupled Plasma-Optical Emission Spectrometers (ICP-OES; iCAP 6300 Duo, Thermofisher). Samples (1 ml each) were digested in a glass vial over a heating plate with aqua regia (2 ml), repeating the treatment for four times. The explant samples were digested over a heating plate with a solution of HNO3/H2O2 30% m/m (3/1, 2 ml) for two times, followed by aqua regia (2 ml) for three times. The dry residues were dissolved in a 0.5 M HCl aqueous solution and diluted. The limit of detection (lod) calculated for gold was 0.01 ppm.
Nanoparticle administration in vivo
Mice were maintained under pathogen-free conditions at San Raffaele Hospital mouse facility (Milan, Italy). All efforts were made to minimize animal suffering and to reduce the number of mice used in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC). Five weeks CD1 (Charles Rivers) females were given an injection of anesthetic (2,2,2-tribromoethanol, 10 mg/ml; 1/27 of body weight), then 10 µl of Cy 5.5-AuNPs (0.11 µg/µl) were injected within the cisterna magna of mice using a 27-gauge stainless steel needle curved (40°) at 3.5 mm from the tip, so that it was J-shaped . IV delivery was obtained injecting mice in the tail vein with 200 µl of Cy5.5-AuNPs (0.11 µg/µl). Intra parenchymal injection was obtained by delivering 1 μl of Cy 5.5-AuNPs (1.1 µg/µl) in the brain by a single stereotaxic injection at the following coordinates: A − 0.5, 0; L, + 1.2; and D, − 0.8 . Control mice received injections of soluble Cy5.5 or vehicle (sterile saline). To calculate the appropriate amount of Cy5.5 to be delivered into the cisterna magna, we compared curves of fluorescence from serial dilutions (dilution factor = 10) of Cy5.5 and Cy5.5-AuNPs, using the IVIS SpectrumCT System. Control mice received Cy5.5 at the concentration that produced the same fluorescence level of the Cy5.5-AuNPs used in our experiments. At the sacrifice (2, 5, 15 and 30 days after the delivery of particles), mice were given an overdose of anesthetic drugs and were transcardially perfused with saline followed by 80/100 ml 4% paraformaldehyde in PBS 1×, pH 7.2 (Sigma). Brains were post fixed in the same solution for 12 h at + 4 °C. Tissues were cryoprotected in PBS/30% Sucrose (Sigma), embedded in OCT inclusion media and stored at − 80 °C before processing. The metal content in brain explants was determined by ICP-OES. Mice were perfused with sterile saline and brains homogenized in PBS solutions. Sample were digested in a glass vial over a heating plate with aqua regia according our published methods . The dry residuals were dissolved in a HCl aqueous solution 0.5 M and properly diluted.
In vivo imaging
Mice images were acquired by placing the animals at 37 °C under gaseous anesthesia (2–3% isoflurane and 1 l/min oxygen). FLI was performed by IVIS Spectrum-CT System (Perkin Elmer), equipped with a low noise, back-thinned, back-illuminated CCD camera cooled at − 90 °C and a with quantum efficiency in the visible range > 85%. Images were obtained using the following settings: exposure time = auto, binning = 8, f = 2 and a field of view equal to 13 cm (field C); when needed spectral unmixing, FLI was obtained using the following excitation/emission filters: 640/680, 640/700, 640/720, 640/740, 675/720, 675/740, 675/760 nm. Acquisitions were done before and after the injection of particles with the following time sampling: 1 h, and 1, 2, 3, 4, 7, 10, 16, 25 days after the delivery of Cy5.5-AuNPs. Analyses were done in a region of interest (ROI) overlapping the brain, measuring the radiant efficiency within this ROI using images acquired with the 675/720 filters. The FR(ti) was calculated on ROI sampled at different time points (ti) and normalized on images acquired before injection or particles (t0) to quantify the magnitude of the fluorescence signal: FR(ti) = [ROI(ti))/(ROI(t0)]. Spectral un-mixing of the FLI data was performed on selected images in order to show the specificity of the fluorescence signal over the tissue auto-fluorescence. All the images were acquired and analyzed using Living Image 4.5 (Perkin Elmer).
Immunofluorescence and electron microscopy
Immunofluorescence and electron microscopy have been done according the following methods [49, 50, 51]. Brains were sagittal or coronal sectioned (20 µm) and one section every 250 µm was used for immunofluorescence. Slides were washed in PBS 1× and incubated with the following blocking buffer: PBS 1×, BSA 1 mg/ml, FBS 10%, Triton 0.1% (Sigma). Primary antibodies were diluted in the same buffer and incubated on section for 12 h at + 4 °C. Secondary antibodies (Alexa-flour conjugated) were incubated according to manufacturer’ instructions, then sections were cover slipped with Dako mounting mix. The following antibodies were used: mouse α-NeuN (Millipore, 1:800); rabbit α-MBP (Millipore) 1: 500; rabbit α-Iba1 (Wako) 1:400; rabbit α-GFAP (Dako) 1:1000. Secondary, Alexafluor 488-conjugated antibodies were used according to manufactures’ instructions. Acquisitions were performed with a Leica SP8 confocal microscopy equipped with a 40× objective and with super-sensitive HyD detectors. Fluorescence was recorded as square 8-bit images (1024 × 1024 pixels) and stored as separate image stacks for each channel. Alignment of images to obtain largest field of view of coronal sections was done by automatic stitching of stack images using the Leica (Las-X, Leica). Acquisition of fluorescence from Au was done according published methods . We used an excitation wavelength of 532 nm, while signals were acquired in the 594–640 nm window. Images showed the maximal projections of Z-stacks acquired with a 0.8 µm step or cross sections of selected cells acquired with 0.3 µm step. Images were pseudo-colored using Las-X software. For EM analysis, brains were post-fixed in 0.12 M phosphate buffer supplemented with 2% glutaraldehyde, and further sectioned to get a region encompassing the 4th ventricle and the cerebellum. These parts were further post-fixed with osmium tetroxide and embedded in Epon (Fluka, Buchs, Switzerland). Ultrathin sectioning of the CNS allowed the generation of 70 nm sections that were imaged by a transmission electron microscope (LEO 912AB). In vitro quantification of Cy5.5-AuNPs fluorescence were performed using the FLI (FLI) acquired with IVIS SpectrumCT System scanner (Perkin Elmer).
Primary hippocampal cultures and sytox determination
Neurons were obtained from the hippocampus of CD1 (Charles Rivers) mice at the embryonic stage of E17.5. Hippocampi were mechanically dissociated in cold HBSS supplemented with 0.6% glucose, 5 mM HEPES (pH 7.4) (Sigma Aldrich). Cells were suspended in culture medium containing Neurobasal Medium (Thermo Fisher Scientific) supplemented with: N2 (Thermo Fisher Scientific), B27 (GIBCO), 5 mM HEPES (pH 7.4), 0.6% glucose (Sigma Aldrich) and 0.5% glutamine (Thermo Fisher Scientific) in the absence of antimitotic and antibiotic drugs. Fifteen days after plating neurons were incubated with increasing amounts of Cy 5.5-AuNPs (1, 0.1, 0.01 and 0.001 mg/ml) for 24 h. Percentages of dying cells were estimated labelling cells with Sytox and Hoechst (Molecular Probes). Automated imaging was performed using the ArrayScan® (ThermoFisher) equipped with a 40× air objective. More than 300 fields per conditions have been assayed for the statistical evaluation of cell death.
Data are expressed with the mean ± standard error (± S.D.). Normality of dataset was assessed in each experiment by applying either Kolmogorov–Smirnov test (with Dallas–Wilkinson–Lille for P value) or Skewness test. Comparisons were done using: unpaired t-test, one-way analysis of variance (ANOVA), followed by Tukey post hoc test. Statistical tests were carried out using PRISM5.01 (GraphPad Software).
AS performed in vivo analysis of Cy5.5-AuNPs, MG performed in situ analysis of AuNPs distribution, LP and DA did the synthesis and the characterization of particles used in this study, GM and PS conceived the study and revised the manuscript, AM and LM are the corresponding authors. They designed the study, revised the manuscript and also provided funding support. All authors read and approved the final manuscript.
LM and GM are supported by an unrestricted grant from BMW, Italy. LP acknowledges MIUR-Italy (contract 2015RNWJAM 002) for financial support. We thank people from the Alembic Facility of the San Raffaele Hospital for their technical help and Marcello Marelli (ISTM-CNR) for AuNPs TEM. We also thank Annamaria Finardi for her technical assistance in mouse handling.
The authors declare that they have no competing interests.
Availability of data and materials
Data regarding each experiment are available from corresponding authors on reasonable request.
Consent for publication
This manuscript is approved by all authors for the submission.
Ethics approval and consent to participate
The authors state that they obtained the appropriate institutional approval for the use of mice in this study.
This work was supported by BMW (Italy, 2018 unrestricted grant) and by MIUR (2015RNWJAM 002).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Vo-Dinh T, Inman BA. What potential does plasmonics-amplified synergistic immuno photothermal nanotherapy have for treatment of cancer? Nanomed Nanotechnol Biol Med. 2018;13:139–44.Google Scholar
- 4.Velasco-Aguirre C, Morales F, Gallardo-Toledo E, Guerrero S, Giralt E, Araya E, Kogan MJ. Peptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approaches. Int J Nanomed. 2015;10:4919–36.Google Scholar
- 7.Key J, Leary JF. Nanoparticles for multimodal in vivo imaging in nanomedicine. Int J Nanomed. 2014;9:711–26.Google Scholar
- 22.Gromnicova R, Yilmaz CU, Orhan N, Kaya M, Davies H, Williams P, Romero IA, Sharrack B, Male D. Localization and mobility of glucose-coated gold nanoparticles within the brain. Nanomed Nanotechnol Biol Med. 2016;11:617–25.Google Scholar
- 25.Mufson EJ, Kroin JS, Liu YT, Sobreviela T, Penn RD, Miller JA, Kordower JH. Intrastriatal and intraventricular infusion of brain-derived neurotrophic factor in the cynomologous monkey: distribution, retrograde transport and co-localization with substantia nigra dopamine-containing neurons. Neuroscience. 1996;71:179–91.CrossRefGoogle Scholar
- 26.Wersall P, Ohlsson I, Biberfeld P, Collins VP, von Krusenstjerna S, Larsson S, Mellstedt H, Boethius J. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother CII. 1997;44:157–64.CrossRefGoogle Scholar
- 27.Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:201–6.CrossRefGoogle Scholar
- 30.Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffini F, Adorini L, Glorioso JC, Comi G, Martino G. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther. 2001;8:13–9.CrossRefGoogle Scholar
- 35.de Ceglia R, Chaabane L, Biffi E, Bergamaschi A, Ferrigno G, Amadio S, Del Carro U, Mazzocchi N, Comi G, Bianchi V, et al. Down-sizing of neuronal network activity and density of presynaptic terminals by pathological acidosis are efficiently prevented by diminazene aceturate. Brain Behav Immun. 2015;45:263–76.CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.